DelSiTech Announces Closing of EUR 10 Million Financing Round to Advance its Silica-Based Drug Delivery Technology Platform
- New investment from DRW Venture Capital LLC and Tolmar International Ltd
- Funds will be used to advance its proprietary, silica-based, drug delivery technology platform towards the clinic and further build DelSiTech
Turku, Finland – 16th January 2024. Clinical-stage drug delivery and development company DelSiTech, today announces the successful completion of a EUR 10 million financing round, the largest single financing round in the Company’s history. The financing was co-led by new investors DRW Venture Capital LLC, headquartered in Chicago, IL, USA, and Tolmar International Ltd, based in Dublin, Ireland, which together contributed more than EUR 9 million. The remaining financing was funded by existing DelSiTech shareholders.
